O2 RegenTech

O2 RegenTech

Closed: Apr. 2025

About this raise

O2 RegenTech, with a valuation of $6.8 million, is raising funds on NetCapital. The company is using its proprietary biopolymer technology to commercialize easy-to-use wound care solutions. O2 RegenTech’s first product is called OXAID and is a moist, oxygenating, and antimicrobial dressing that promotes chronic wound healing. It is a one-of-a-kind wound solution that is cost-effective and easy to use and helps chronic wounds heal faster and at a lower cost than other oxygen delivery systems. Dr. Andreas Inmann and Dr. Nic Leipzig founded O2 RegenTech in July 2013. The current crowdfunding campaign has a minimum target of $10,002.80 and a maximum target of $612,000. The campaign proceeds will be used for product development, regulatory affairs, operations, payroll, and biocompatibility testing.

Expand

Investment Overview

Not Funded: $2,033

Deal Terms

Total Commitments

Platform
Netcapital
Start Date
11/08/2023
Close Date
04/30/2025
Min. Goal
$10,003
Max Goal
$612,000
Min. Investment

$102

Security Type

Equity - Common

Company Stage

Early Stage

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$6.80

Pre-Money Valuation

$6,800,000

Company & Team

Company

Year Founded
2013
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B2C
Margin
Medium
Capital Intensity
High
Location
Akron, Ohio
Business Type
Growth
Company Website
Visit Website

Team

Employees
4
Prior Founder Exits?
No
Founder Name
Nic Leipzig
Title
Chief Scientific Officer
Founder Name
Andreas Inmann
Title
President and CEO

Financials

 Revenue
$0
as of FY2023
 Monthly Burn
$2,338
as of FY2023
 Runway
0.8 months
as of FY2023

Summary Profit and Loss Statement

FY 2023 FY 2022

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-28,055

$-18,280

Summary Balance Sheet

FY 2023 FY 2022

Cash

$1,981

$1,032

Accounts Receivable

$0

$0

Total Assets

$1,981

$1,032

Short-Term Debt

$111,693

$67,689

Long-Term Debt

$320,193

$291,189

Total Liabilities

$431,886

$358,878

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$0
VC Backed?
No
Close Date Platform Valuation Total Raised Security Type Status Reg Type
04/30/2025 Netcapital $6,800,000 $2,033 Equity - Common Not Funded RegCF
Create a free account today to gain access to Kingscrowd analytics.
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
O2 RegenTech on NetCapital 2023
Platform: Netcapital
Security Type: Equity - Common
Valuation: $6,800,000
Price per Share: $6.80

Follow company

Follow O2 RegenTech on NetCapital 2023

Buy O2 RegenTech's Deal Report

Warning: according to the close date for this deal, O2 RegenTech may no longer be accepting investments.

O2 RegenTech Deal Report

Get Kingscrowd's comprehensive report on O2 RegenTech including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether O2 RegenTech is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the O2 RegenTech deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge